Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 9/20 | 0.78 |
| ▸ | MMP13 | P45452 | 3/20 | 0.62 |
| ▸ | MMP3 | P08254 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | NAT1 | P18440 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189394 | 1.00 | ADAMTS5 (0.78) | ADAMTS5MMP13MMP3GSK3BNAT1 | |
| SCHEMBL8166386 | 0.81 | NAT1 (0.74) | ADAMTS5MMP13MMP3GSK3BNAT1 | |
| SCHEMBL8166383 | 0.81 | NAT1 (0.74) | ADAMTS5MMP13MMP3GSK3BNAT1 | |
| SCHEMBL18103023 | 0.78 | ADAMTS5 (1.00) | ADAMTS5MMP13MMP3GSK3BNAT1 | |
| SCHEMBL8172889 | 0.78 | ADAMTS5 (0.71) | ADAMTS5MMP13MMP3AKR1B1TDP1 | |
| SCHEMBL8172886 | 0.78 | ADAMTS5 (0.71) | ADAMTS5MMP13MMP3AKR1B1TDP1 | |
| SCHEMBL12891792 | 0.78 | AKR1B1 (0.81) | ADAMTS5MMP13MMP3AKR1B1 | |
| SCHEMBL1247918 | 0.78 | AKR1B1 (0.81) | ADAMTS5MMP13MMP3AKR1B1 | |
| SCHEMBL1247917 | 0.78 | AKR1B1 (0.81) | ADAMTS5MMP13MMP3AKR1B1 | |
| SCHEMBL8308267 | 0.77 | MMP13 (1.00) | ADAMTS5MMP13MMP3GSK3BNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000018748-A1 | RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |